Waiting for new drugs for rare disorders in Canada
This series by MLI senior fellows John Adams and Nigel Rawson is an in-depth look at the disadvantages faced by Canadians with rare disorders in accessing needed, innovative drugs.
-
Time for an intervention – an urgent call to end “gender-affirming” treatments for children: J. Edward Les for Inside Policy
-
Canadian Competitiveness in Resource Development – A Post-Mortem: Heather Exner-Pirot
-
The Governor General deserves better, but we deserve impartiality: Philippe Lagassé for Inside Policy
-
Widespread shortages, skyrocketing costs: the growing calamity that is government-controlled child care
-
Canada’s resource sector: protecting the Golden Goose
